Angiosarcoma
2 papers study it4 more mention it
- Cells2
Trial sponsors
Company1 trialPhase 2148 people
Company1 trialPhase 1499 people
QuantumLeap Healthcare Collaborative
1 trialPhase 25,000 people
1 trialPhase 280 people
Washington University School of Medicine
1 trialPhase 273 people
1 trialPhase 270 people
Instituto do Cancer do Estado de São Paulo
1 trialPhase 228 people
1 trialPhase 226 people
Latest
Current Treatment Options in Oncology
PAI-1 in Skin Malignancies: a Central Regulator of Tumor Progression and Therapeutic Resistance
ReviewSkin
Research Square
Younger Age Is Associated with Favorable Outcomes in Adult Dogs with Hemangiosarcoma Receiving Adjuvant Doxorubicin Chemotherapy: Results from the PRO-DOX Study
Preprint: experiments in 20 dogsInterventions
European Journal of Human Genetics
POT1 tumour predisposition: a broader spectrum of associated malignancies and proposal for additional screening program
Case series of 37 peoplePopulations
The Journal of Investigative Dermatology
Chemo-Senolytic Therapeutic Potential against Angiosarcoma
Experiments in human cellsSenolytics
British Journal of Pharmacology
STAT1- and NFAT-independent amplification of purinoceptor function integrates cellular senescence with interleukin-6 production in preadipocytes
Experiments in mouse cellsCellular senescence
Journal of Medical Genetics
POT1 mutation spectrum in tumour types commonly diagnosed among POT1-associated hereditary cancer syndrome families
Study in peopleMechanisms